Somafostatin inhibits growth hormone, thyroid stimulating hormone, insulin, and glucagon secretion. It reduces splanchnic blood flow and gastric acid secretion, making it useful for esophageal varices bleeding and acute pancreatitis. Administration requires careful dosing and monitoring for adverse…
Somafostatin exhibits several inhibitory actions on key hormones and digestive secretions. It suppresses the release of growth hormone, thyroid stimulating hormone, insulin, and pancreatic glucagon. The drug also inhibits gastric acid secretion when stimulated by a test meal and by 5 pentagastrin, and it reduces the release of gastrin and pepsin.
A significant effect of somafostatin is its ability to reduce splanchnic blood flow. This leads to decreased portal pressure, lower blood pressure, and reduced collateral circulation, which ultimately diminishes blood flow to the liver. The drug also reduces the secretion of the gallbladder and pancreas, as well as the internal and external secretions of the stomach and small intestine. This combined effect reduces the activity of pancreatic cell protection. Additionally, somafostatin directly inhibits glucagon secretion and affects gastrointestinal absorption and nutritional functions to a certain degree, similar to liraglutide.
Somafostatin is indicated for a range of serious medical conditions. It is used for esophageal varices bleeding that results from portal hypertension. The drug also treats gastrointestinal bleeding caused by peptic ulcer, stress ulcer, and erosive gastritis. It is employed in the prevention and treatment of acute pancreatitis and its complications.
Furthermore, somafostatin serves as adjuvant therapy for conditions involving the pancreas, gall bladder, and intestinal fistula. It is also indicated for acromegaly, gastrinoma, insulinoma, and vasoactive intestinal peptide tumors. These diverse applications highlight the drug's broad therapeutic potential.
For upper gastrointestinal bleeding, specifically esophageal varices, treatment begins with an intravenous infusion of 250μg administered over 3 to 5 minutes. This is followed by a continuous infusion of 250μg per hour, which should be maintained for 48 to 72 hours after the bleeding has stopped.
In cases of pancreas, gall bladder, and intestinal fistula, the patient starts with a 250μg per hour infusion and continues until the fistula closes, after which a successor therapy is given for 1 to 3 days. For acute pancreatitis, a continuous infusion of 250μg per hour is administered for 72 to 120 hours. To prevent complications after pancreatic surgery, the infusion is continued for five days in a row. For patients undergoing ERCP examination, the product should be administered within 2 to 3 hours before the surgery.
A small number of patients may experience vertigo, tinnitus, and flushing. If the injection rate exceeds 50μg per minute, nausea and vomiting can occur. Regarding precautions, somafostatin is contraindicated in individuals with allergies, as well as in pregnant and lactating women.
At the beginning of administration, a temporary decline in blood sugar may occur. Therefore, insulin-dependent diabetics should check their blood sugar every 3 to 4 hours. The drug can extend the hypnotic effect time of hexobarbital and may aggravate the role of pentene tetrazole, meaning the two products cannot be used simultaneously. The product should be administered alone and must not be combined with other drugs. Additionally, arterial bleeding is not an indication for somatostatin.
Somafostatin is available as an injection in two strengths: 250μg and 3mg. Modern scientific advances in various diseases have benefited from high-level peptide products such as deslorelin acetate, GLP-1 7-36 amide acetate, teduglutide, and others. This is why increasing numbers of researchers are focusing on peptide studies.
Peptides referenced: Liraglutide, Growth Hormone, VIP (Vasoactive Intestinal Peptide), Somatostatin, Glucagon, Teduglutide, GLP-1.
Related reading: Bachem and Novo Nordisk redesign SPPS for green chemistry, Practical Guide to Solid Phase Peptide Synthesis Covers Key Methods, 1 Drugs and Dementia: New Report Examines Alzheimer’s Research, DSIP Peptide: Sleep Signaling and Circadian Rhythm Research in Canada.